Lantheus Holdings Inc (NASDAQ:LNTH) Director Brian A. Markison sold 5,000 shares of Lantheus stock in a transaction that occurred on Wednesday, June 19th. The shares were sold at an average price of $27.40, for a total value of $137,000.00. Following the completion of the sale, the director now directly owns 42,467 shares in the company, valued at approximately $1,163,595.80. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Shares of Lantheus stock opened at $27.85 on Monday. Lantheus Holdings Inc has a 52-week low of $12.59 and a 52-week high of $28.48. The company has a market capitalization of $1.08 billion, a P/E ratio of 29.63, a PEG ratio of 2.09 and a beta of 1.46. The company has a current ratio of 4.57, a quick ratio of 3.82 and a debt-to-equity ratio of 3.16.

Lantheus (NASDAQ:LNTH) last posted its quarterly earnings results on Tuesday, April 30th. The medical equipment provider reported $0.28 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.25 by $0.03. The firm had revenue of $86.51 million during the quarter, compared to the consensus estimate of $86.80 million. Lantheus had a return on equity of 59.57% and a net margin of 12.17%. Research analysts forecast that Lantheus Holdings Inc will post 1.11 earnings per share for the current year.

A number of equities research analysts recently issued reports on LNTH shares. TheStreet raised Lantheus from a “c+” rating to a “b” rating in a research report on Monday, March 4th. BidaskClub lowered Lantheus from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, June 11th. Finally, Zacks Investment Research raised Lantheus from a “hold” rating to a “buy” rating and set a $27.00 target price on the stock in a research report on Thursday, April 4th. Two analysts have rated the stock with a hold rating and three have given a buy rating to the company. The company presently has an average rating of “Buy” and a consensus target price of $23.33.

Hedge funds have recently bought and sold shares of the business. PNC Financial Services Group Inc. grew its stake in Lantheus by 51.4% in the fourth quarter. PNC Financial Services Group Inc. now owns 1,694 shares of the medical equipment provider’s stock valued at $26,000 after purchasing an additional 575 shares in the last quarter. First Quadrant L P CA bought a new position in Lantheus in the first quarter valued at approximately $95,000. Advisor Group Inc. grew its stake in Lantheus by 1,837.2% in the fourth quarter. Advisor Group Inc. now owns 4,378 shares of the medical equipment provider’s stock valued at $69,000 after purchasing an additional 4,152 shares in the last quarter. Anderson Fisher LLC bought a new position in Lantheus in the first quarter valued at approximately $112,000. Finally, Meeder Asset Management Inc. grew its stake in Lantheus by 212.8% in the first quarter. Meeder Asset Management Inc. now owns 4,757 shares of the medical equipment provider’s stock valued at $115,000 after purchasing an additional 3,236 shares in the last quarter. Hedge funds and other institutional investors own 92.55% of the company’s stock.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases worldwide. Its principal products include DEFINITY, a microbubble contrast agent used in ultrasound exams of the heart; and TechneLite, a technetium generator that provides the nuclear material used in nuclear medicine procedures.

Recommended Story: What is meant by a buy rating?

Insider Buying and Selling by Quarter for Lantheus (NASDAQ:LNTH)

Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with MarketBeat.com's FREE daily email newsletter.